Search

Your search keyword '"Jacobson, Judith S."' showing total 255 results
Start Over Author "Jacobson, Judith S." Search Limiters Peer Reviewed
255 results on '"Jacobson, Judith S."'

1. Heterogeneous genetic architectures of prostate cancer susceptibility in sub-Saharan Africa

Author

Janivara, Rohini, Chen, Wenlong C., Hazra, Ujani, Baichoo, Shakuntala, Agalliu, Ilir, Kachambwa, Paidamoyo, Simonti, Corrine N., Brown, Lyda M., Tambe, Saanika P., Kim, Michelle S., Harlemon, Maxine, Jalloh, Mohamed, Muzondiwa, Dillon, Naidoo, Daphne, Ajayi, Olabode O., Snyper, Nana Yaa, Niang, Lamine, Diop, Halimatou, Ndoye, Medina, Mensah, James E., Abrahams, Afua O. D., Biritwum, Richard, Adjei, Andrew A., Adebiyi, Akindele O., Shittu, Olayiwola, Ogunbiyi, Olufemi, Adebayo, Sikiru, Nwegbu, Maxwell M., Ajibola, Hafees O., Oluwole, Olabode P., Jamda, Mustapha A., Pentz, Audrey, Haiman, Christopher A., Spies, Petrus V., van der Merwe, André, Cook, Michael B., Chanock, Stephen J., Berndt, Sonja I., Watya, Stephen, Lubwama, Alexander, Muchengeti, Mazvita, Doherty, Sean, Smyth, Natalie, Lounsbury, David, Fortier, Brian, Rohan, Thomas E., Jacobson, Judith S., Neugut, Alfred I., Hsing, Ann W., Gusev, Alexander, Aisuodionoe-Shadrach, Oseremen I., Joffe, Maureen, Adusei, Ben, Gueye, Serigne M., Fernandez, Pedro W., McBride, Jo, Andrews, Caroline, Petersen, Lindsay N., Lachance, Joseph, and Rebbeck, Timothy R.

Published
2024
Full Text
View/download PDF

3. Multimorbidity and overall survival among women with breast cancer: results from the South African Breast Cancer and HIV Outcomes Study

Author

Ayeni, Oluwatosin A., Joffe, Maureen, Mapanga, Witness, Chen, Wenlong Carl, O’Neil, Daniel S., Phakathi, Boitumelo, Nietz, Sarah, Buccimazza, Ines, Čačala, Sharon, Stopforth, Laura W., Jacobson, Judith S., Crew, Katherine D., Neugut, Alfred I., Ramiah, Duvern, Ruff, Paul, Cubasch, Herbert, Chirwa, Tobias, McCormack, Valerie, Micklesfield, Lisa K., and Norris, Shane A.

Published
2023
Full Text
View/download PDF

7. The impact of HIV on non-adherence for tamoxifen among women with breast cancer in South Africa

Author

Ayeni, Oluwatosin A., Chiwambutsa, Shingirai, Chen, Wenlong Carl, Kapungu, Nyasha, Kanji, Comfort, Thelingwani, Roslyn, Murugan, Nivashni, Mathiba, Rofhiwa, Phakathi, Boitumelo, Nietz, Sarah, Ramiah, Duvern, O’Neil, Daniel S., Jacobson, Judith S., Ruff, Paul, Cubasch, Herbert, Chirwa, Tobias, Joffe, Maureen, Masimirembwa, Collen, and Neugut, Alfred I.

Published
2023
Full Text
View/download PDF

8. Overall and central obesity and prostate cancer risk in African men

Author

Agalliu, Ilir, Lin, Wei-Kaung Jerry, Zhang, Janice S., Jacobson, Judith S., Rohan, Thomas E., Adusei, Ben, Snyper, Nana Yaa F., Andrews, Caroline, Sidahmed, Elkhansa, Mensah, James E., Biritwum, Richard, Adjei, Andrew A., Okyne, Victoria, Ainuson-Quampah, Joana, Fernandez, Pedro, Irusen, Hayley, Odiaka, Emeka, Folasire, Oluyemisi Folake, Ifeoluwa, Makinde Gabriel, Aisuodionoe-Shadrach, Oseremen I., Nwegbu, Maxwell Madueke, Pentz, Audrey, Chen, Wenlong Carl, Joffe, Maureen, Neugut, Alfred I., Diallo, Thierno Amadou, Jalloh, Mohamed, Rebbeck, Timothy R., Adebiyi, Akindele Olupelumi, and Hsing, Ann W.

Published
2022
Full Text
View/download PDF

12. A comparison of complete pathologic response rates following neoadjuvant chemotherapy among South African breast cancer patients with and without concurrent HIV infection

Author

Nietz, Sarah, O’Neil, Daniel S, Ayeni, Oluwatosin, Chen, Wenlong Carl, Joffe, Maureen, Jacobson, Judith S, Neugut, Alfred I, Ruff, Paul, Mapanga, Witness, Buccimazza, Ines, Singh, Urishka, Čačala, Sharon, Stopforth, Laura, Phakathi, Boitumelo, Chirwa, Tobias, and Cubasch, Herbert

Published
2020
Full Text
View/download PDF

21. The Impact of HIV Infection on Neoadjuvant and Adjuvant Chemotherapy Relative Dose Intensity in South African Patients with Breast Cancer.

Author

O'Neil, Daniel S, Ayeni, Oluwatosin A, Farrow, Hayley A, Chen, Wenlong Carl, Demetriou, Georgia, Buccimazza, Ines, Čačala, Sharon, Stopforth, Laura W, Joffe, Maureen, Antoni, Michael H, Lopes, Gilberto, Pumpalova, Yoanna S, Mapanga, Witness, Jacobson, Judith S, Crew, Katherine D, Neugut, Alfred I, Ruff, Paul, and Cubasch, Herbert

Subjects
ADJUVANT chemotherapy, HIV infections, GRANULOCYTE-colony stimulating factor, REGRESSION analysis, CANCER patients, DESCRIPTIVE statistics, RESEARCH funding, COMBINED modality therapy, BREAST tumors, DOSE-response relationship in biochemistry, COMORBIDITY
Abstract

Introduction In the South African Breast Cancer and HIV Outcomes (SABCHO) study, we previously found that breast cancer patients living with HIV and treated with neoadjuvant chemotherapy achieve lower rates of complete pathologic response than patients without HIV. We now assess the impact of comorbid HIV on receipt of timely and complete neoadjuvant and adjuvant chemotherapy. Materials and Methods Since June 2015, the SABCHO study has collected data on women diagnosed with breast cancer at 6 South African hospitals. We selected a sample of participants with stages I-III cancer who received ≥2 doses of neoadjuvant or adjuvant chemotherapy. Data on chemotherapies prescribed and received, filgrastim receipt, and laboratory values measured during treatment were captured from patients' medical records. We calculated the mean relative dose intensity (RDI) for all prescribed chemotherapies. We tested for association between full regimen RDI and HIV status, using linear regression to control for demographic and clinical covariates, and for association of HIV with laboratory abnormalities. Results The 166 participants living with HIV and 159 without HIV did not differ in median chemotherapy RDI: 0.89 (interquartile range (IQR) 0.77-0.95) among those living with HIV and 0.87 (IQR 0.77-0.94) among women without HIV. Patients living with HIV experienced more grade 3+ anemia and leukopenia than those without HIV (anemia: 10.8% vs. 1.9%, P =.001; leukopenia: 8.4% vs. 1.9%, P =.008) and were more likely to receive filgrastim (24.7% vs. 10.7%, P =.001). Conclusions HIV status did not impact neoadjuvant or adjuvant chemotherapy RDI, although patients with breast cancer living with HIV experienced more myelotoxicity during treatment. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

24. Effects of Genetic Polymorphisms of Drug Metabolizing Enzymes and co‐Medications on Tamoxifen Metabolism in Black South African Women with Breast Cancer.

Author

Chiwambutsa, Shingirai M., Ayeni, Oluwatosin, Kapungu, Nyasha, Kanji, Comfort, Thelingwani, Roslyn, Chen, Wenlong Carl, Mokone, Dikeledi H., O'Neil, Daniel S., Neugut, Alfred I., Jacobson, Judith S., Ruff, Paul, Cubasch, Herbert, Joffe, Maureen, and Masimirembwa, Collen

Subjects
BLACK South Africans, SOUTH Africans, GENETIC polymorphisms, LIQUID chromatography-mass spectrometry, CANCER patients
Abstract

Clinical outcomes of tamoxifen (TAM) treatment show wide interindividual variability. Comedications and genetic polymorphisms of enzymes involved in TAM metabolism contributes to this variability. Drug–drug and drug–gene interactions have seldom been studied in African Black populations. We evaluated the effects of commonly co‐administered medicines on TAM pharmacokinetics in a cohort of 229 South African Black female patients with hormone‐receptor positive breast cancer. We also investigated the pharmacokinetic effects of genetic polymorphism in enzymes involved in TAM metabolism, including the variants CYP2D6*17 and *29, which have been mainly reported in people of African descent. TAM and its major metabolites, N‐desmethyltamoxifen (NDM), 4‐OH‐tamoxifen, and endoxifen (ENDO), were quantified in plasma using the liquid chromatography‐mass spectrometry. The GenoPharm open array was used to genotype CYP2D6, CYP3A5, CYP3A4, CYP2B6, CYP2C9, and CYP2C19. Results showed that CYP2D6 diplotype and CYP2D6 phenotype significantly affected endoxifen concentration (P < 0.001 and P < 0.001). CYP2D6*17 and CYP2D6*29 significantly reduced the metabolism of NDM to ENDO. Antiretroviral therapy had a significant effect on NDM levels and the TAM/NDM and NDM/ENDO metabolic ratios but did not result in significant effects on ENDO levels. In conclusion, CYP2D6 polymorphisms affected endoxifen concentration and the variants CYP2D6*17 and CYP2D6*29 significantly contributed to low exposure levels of ENDO. This study also suggests a low risk of drug–drug interaction in patients with breast cancer on TAM. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

32. Drivers of disparities in stage at diagnosis among women with breast cancer: South African breast cancers and HIV outcomes cohort.

Author

Mapanga, Witness, Norris, Shane A., Craig, Ashleigh, Ayeni, Oluwatosin A., Chen, Wenlong C., Jacobson, Judith S., Neugut, Alfred I., Ruff, Paul, Cubasch, Herbert, O'Neil, Daniel S., Buccimazza, Ines, Čačala, Sharon, Stopforth, Laura W., Farrow, Hayley A., Nietz, Sarah, Phakathi, Boitumelo, Chirwa, Tobias, McCormack, Valerie A., and Joffe, Maureen

Subjects
HIV, CANCER patients, BREAST cancer, CANCER prognosis, CITY dwellers, RURAL population
Abstract

Objective: In low- and middle-income countries (LMICs), advanced-stage diagnosis of breast cancer (BC) is common, and this contributes to poor survival. Understanding the determinants of the stage at diagnosis will aid in designing interventions to downstage disease and improve survival from BC in LMICs. Methods: Within the South African Breast Cancers and HIV Outcomes (SABCHO) cohort, we examined factors affecting the stage at diagnosis of histologically confirmed invasive breast cancer at five tertiary hospitals in South Africa (SA). The stage was assessed clinically. To examine the associations of the modifiable health system, socio-economic/household and non-modifiable individual factors, hierarchical multivariable logistic regression with odds of late-stage at diagnosis (stage III-IV), was used. Results: The majority (59%) of the included 3497 women were diagnosed with late-stage BC disease. The effect of health system-level factors on late-stage BC diagnosis was consistent and significant even when adjusted for both socio-economic- and individual-level factors. Women diagnosed in a tertiary hospital that predominantly serves a rural population were 3 times (OR = 2.89 (95% CI: 1.40–5.97) as likely to be associated with late-stage BC diagnosis when compared to those diagnosed at a hospital that predominantly serves an urban population. Taking more than 3 months from identifying the BC problem to the first health system entry (OR = 1.66 (95% CI: 1.38–2.00)), and having luminal B (OR = 1.49 (95% CI: 1.19–1.87)) or HER2-enriched (OR = 1.64 (95% CI: 1.16–2.32)) molecular subtype as compared to luminal A, were associated with a late-stage diagnosis. Whilst having a higher socio-economic level (a wealth index of 5) reduced the probability of late-stage BC at diagnosis, (OR = 0.64 (95% CI: 0.47–0.85)). Conclusion: Advanced-stage diagnosis of BC among women in SA who access health services through the public health system was associated with both modifiable health system-level factors and non-modifiable individual-level factors. These may be considered as elements in interventions to reduce the time to diagnosis of breast cancer in women. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

35. Prevalence of Monoclonal Gammopathy of Undetermined Significance in Black South African Men.

Author

Cicero, Kara I., Joffe, Maureen, Patel, Moosa, Chiuzan, Codruta, Pentz, Audrey, Ruff, Paul, Lentzsch, Suzanne, Leng, Siyang, Jacobson, Judith S., Rebbeck, Timothy R., and Neugut, Alfred I.

Abstract

Background: Both multiple myeloma and its precursor, monoclonal gammopathy of undetermined significance (MGUS), occur twice as often within Black compared with White populations, suggesting that racial disparities lie within the development of MGUS. Nonetheless, MGUS has been studied mainly in White cohorts; the study that first described the natural history of MGUS was conducted in 97.3% White Olmsted County, Minnesota. Methods: We determined the prevalence of MGUS among 386 Black South African (SA) men >30 years at Chris Hani Baragwanath Hospital in Johannesburg. We conducted serum protein electrophoresis and free light chain quantification to define MGUS by the same criteria as the Olmsted County studies. We also investigated the association between MGUS and various clinical factors, including human immunodeficiency virus (HIV) infection and smoking. Results: We found the prevalence of MGUS to be 8.03% [95% confidence interval (CI), 5.32-10.74], nearly 1.6-fold higher than in the White Olmsted County male population. In a univariable logistic regression model, MGUS was associated with HIV status (OR, 2.39; 95% CI, 0.95-5.49), but in an adjusted model that included body mass index and cigarette use, the association was not statistically significant. Those who were current (vs. never) cigarette smokers were more likely to have MGUS in both univariable (OR, 5.60; 95% CI, 2.16-17.42) and multivariable models (OR, 4.49; 95% CI, 1.63-14.56). Conclusions: The prevalence of MGUS in Black SA men is substantially higher than in White populations and may be associated with HIV status and cigarette use. Impact: Racial disparities in MGUS exist and may be associated with potentially modifiable risk factors. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

47. Prevalence of multimorbidity in men of African descent with and without prostate cancer in Soweto, South Africa.

Author

Mapanga, Witness, Norris, Shane A., Craig, Ashleigh, Pumpalova, Yoanna, Ayeni, Oluwatosin A., Chen, Wenlong Carl, Jacobson, Judith S., Neugut, Alfred I., Muchengeti, Mazvita, Pentz, Audrey, Doherty, Sean, Minkowitz, Shauli, Haffejee, Mohammed, Rebbeck, Tim, and Joffe, Maureen

Subjects
PROSTATE-specific antigen, PROSTATE cancer, PROSTATE cancer patients, DIGITAL rectal examination, CANCER diagnosis, BLOOD pressure measurement, BLOOD pressure testing machines
Abstract

Objective: With increases in chronic disease, men with prostate cancer are likely to have at least one other chronic health condition. The burden and complexity of each additional chronic disease may complicate prostate cancer treatment and reduce survival. In this paper, we describe the frequency of multimorbid chronic diseases, HIV and depression among men in Soweto, South Africa (SA) with and without prostate cancer and determine whether the presence of multimorbid diseases is associated with metastatic and high-risk, non-metastatic prostate cancer. Methods: A population-based case-control study on prostate cancer was conducted among black men in Soweto. All participants completed a baseline survey on sociodemographics, lifestyle, and comorbid medical conditions. All participants completed a depression screening survey and HIV testing at enrolment. Blood pressure measurements and blood testing for fasting glucose, total cholesterol, and high-density lipoprotein were performed on a subset of randomly selected cases and controls. For men with prostate cancer, clinical T staging was assessed with the digital rectal examination, the diagnosis was confirmed with a biopsy and PSA levels were assessed at presentation. The metastatic staging was assessed by bone scans, and this was confirmed with PSMA PET scans, CT scans and X-rays, standard for our resource-constrained setting. Normal PSA scores were used as an inclusion criterion for controls. Results: Of the 2136 men (1095 with prostate cancer and 1041 controls) included in the analysis, 43.0% reported at least one chronic metabolic disease; 24.1% reported two metabolic diseases; 5.3% reported three metabolic diseases; and 0.3% reported four metabolic diseases. Men with prostate cancer were more likely to report a multimorbid chronic metabolic disease compared to controls (p<0.001) and more likely to test positive for HIV (p = 0.05). The majority of men (66.2%) reported at least one metabolic disease, tested negative for HIV and had a negative depression screen. The clinical characteristics of men with prostate cancer, were as follows: 396 (36.2%) had a Gleason score of 8 and above; 552 (51.3%) had a PSA score of >20ng/ml; 233 (21.7%) had confirmed metastatic prostate cancer at diagnosis. Older age was associated with metastatic prostate cancer (OR = 1.043 95% CI:1.02–1.07) and NCCN defined high-risk non-metastatic prostate cancer (OR = 1.03 95% CI:1.01–1.05), whilst being hypertensive was protective (OR = 0.63 95% CI:0.47–0.84 and OR = 0.55 95% CI:0.37–0.83) respectively for metastatic and high-risk, non-metastatic prostate cancer. Conclusion: The high prevalence of multimorbid metabolic diseases and HIV among men with prostate cancer represents a public health concern in South Africa. There is a need to effectively address multiple chronic diseases among men with prostate cancer by incorporating coordinated care models. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results